Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. | Synapse
March 1, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Key Points
The research aims to determine the effectiveness of the lymphocyte-monocyte ratio as a prognostic marker for survival in HCC patients receiving specific treatments.
Analyzed the relationship between lymphocyte-monocyte ratio and patient survival outcomes.
Measured progression-free survival (PFS) and overall survival (OS).
Focused on patients with unresectable hepatocellular carcinoma (HCC) receiving Durvalumab plus Tremelimumab.
Higher lymphocyte-monocyte ratios correlated with better progression-free survival (PFS).
Improved overall survival (OS) was associated with favorable lymphocyte-monocyte ratio levels.
This biomarker may aid in risk stratification for HCC patients in clinical settings.
Abstract
LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.